Wednesday, October 18, 2017
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, acquired ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development.
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Human Longevity (HLI), a San Diego-based, privately held company building a comprehensive database of human genotypes and phenotypes, and the Cleveland Clinic, a nonprofit multispecialty academic medical center, have inked a broad collaboration agreement to first sequence and analyze blood samples from Cleveland Clinic’s GeneBank study of de-identified patients.
The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.
To explain why multiple sclerosis progresses differently in individual patients through new tools, technologies and identification of underlying genetic causes, Biogen Idec has turned to both Google and Columbia University’s Institute for Genomic Medicine for answers.